Gallant Therapeutics Revenue and Competitors

Location

$93M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Gallant Therapeutics's estimated annual revenue is currently $11.3M per year.(i)
  • Gallant Therapeutics's estimated revenue per employee is $155,000
  • Gallant Therapeutics's total funding is $93M.

Employee Data

  • Gallant Therapeutics has 73 Employees.(i)
  • Gallant Therapeutics grew their employee count by 20% last year.

Gallant Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Gallant Therapeutics?

Gallant Therapeutics is a clinical-stage animal health biotechnology company setting a new standard in animal health by harnessing the power of stem cell therapy to treat the root cause of diseases in dogs and cats. Our pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies has the potential to treat a broad range of diseases, including canine and feline osteoarthritis (OA), feline chronic kidney disease (CKD), and others. The first product based on our uterine-derived platform for feline chronic gingivostomatitis (FCGS), is on track for conditional approval by the FDA in 2025. United by a love of and commitment to animals, Gallant’s team includes industry pioneers in veterinary regenerative medicine with deep experience in cell therapy product development, manufacturing and commercialization.

keywords:N/A

$93M

Total Funding

73

Number of Employees

$11.3M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.2M7322%N/A
#2
$9.5M73-1%N/A
#3
$14.4M7333%N/A
#4
$6.6M73-10%N/A
#5
$9.9M734%N/A